Part I: General Information Date Prepared: March 2015 Name: Shuji Ogino Office Address



Download 0.66 Mb.
Page7/7
Date conversion08.07.2018
Size0.66 Mb.
1   2   3   4   5   6   7

14. Nishihara R, Ogino S, Chan AT. Colorectal-cancer incidence and mortality after screening. N Engl J Med 2013;369:2355.


.

15. Nishihara R, Ogino S, Chan AT. Reply. Gastroenterology 2014; in press (published online)


16. Lochhead P, Meyerhardt JA, Fuchs CS, Ogino S. Response. J Natl Cancer Inst 2014; in press (published online).


Case Reports:

1. Ing EB, Kennerdell JS, Olson PR, Ogino S, Rothfus WE. Solitary fibrous tumor of the orbit. Ophthal Plast Reconstr Surg 1998;14:57-61.


2. Ogino S, Al-Kaisi N, Abdul-Karim FW. Cytopathology of oncocytic carcinoid tumor of the lung mimicking granular cell tumor: a case report. Acta Cytol 2000;44:247-250.
3. Ogino S, Franks TJ, Deubner H, Koss MN. Thymohemangiolipoma, a rare histologic variant of thymolipoma: a case report and review of the literature. Ann Diagn Pathol 2000;4:236-239.
4. Ogino S, Franks TJ, Yong M, Koss MN. Extensive squamous metaplasia with cytologic atypia in diffuse alveolar damage mimicking squamous cell carcinoma: a report of 2 cases. Hum Pathol 2002;33:1052-1054.

Thesis
1. Ogino S. Molecular and Population Genetics of Autosomal Recessive Spinal Muscular Atrophy. Tokyo, Japan: University of Tokyo Graduate School of Medicine; 2001.

Other Invited Articles: (Article titles in Japanese are translated.)
1. Ogino S. Getting into a residency in the United States of America. Part I. Igakkai Shimbun (New Medical World Weekly). Edition for Medical Students and Residents. (In Japanese). Igaku-Shoin, Tokyo, Japan. 1996; 2186. Vol.11 No.3:13.
2. Ogino S. Getting into a residency in the United States of America. Part II. Igakkai Shimbun (New Medical World Weekly). Edition for Medical Students and Residents. (In Japanese). Igaku-Shoin, Tokyo, Japan. 1996; 2192 Vol.11 No.4:13.
3. Ogino S. Getting into a residency in the United States of America. Part III. Igakkai Shimbun (New Medical World Weekly). Edition for Medical Students and Residents. (In Japanese). Igaku-Shoin, Tokyo, Japan. 1996; 2199 Vol.11 No.5:12.
4. Ogino S. As a pathology resident in the United States. Igakkai Shimbun (New Medical World Weekly). Edition for Medical Students and Residents. (In Japanese). Igaku-Shoin, Tokyo, Japan. 1998; 2277 Vol.13 No.1:14-15.
5. Ogino S. Pathology residency in the United States: An overview. Byori-to Rinsho (Pathology and Clinical Medicine). (In Japanese) 1998;16:759-760.
6. Ogino S. Pathology residency in the United States: Conferences. Byori-to Rinsho (Pathology and Clinical Medicine). (In Japanese) 1998;16:893.
7. Ogino S. Pathology residency in the United States: Surgical pathology. Byori-to Rinsho (Pathology and Clinical Medicine). (In Japanese) 1998;16:1037-1038.
8. Ogino S. Pathology residency in the United States: Microscopy training. Byori-to Rinsho (Pathology and Clinical Medicine). (In Japanese) 1998;16:1181.
9. Ogino S. Pathology residency in the United States: Autopsy. Byori-to Rinsho (Pathology and Clinical Medicine). (In Japanese) 1998;16:1351-1352.
10. Ogino S. Pathology residency in the United States: Board examination and pathologists in the United States. Byori-to Rinsho (Pathology and Clinical Medicine). (In Japanese). 1998;16:1474.
11. Ogino S. Postgraduate residency program in pathology in the United States. Gendai Iryo (Contemporary Medicine). (In Japanese) 1999;31:2410-2413.
12. Ogino S. The Cooperative Human Tissue Network (CHTN): Its concept and goals. Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2000;18:371.
13. Ogino S. The Cooperative Human Tissue Network (CHTN): Practical issues. Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2000;18:571.
14. Ogino S. Diagnostic molecular pathology in the United States: An update. Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2000;18:858.
15. Ogino S. Quality management in diagnostic molecular pathology. Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2000;18:1111-1112.
16. Ogino S. CAP/ACMG Biochemical and Molecular Genetics Resource Committee and proficiency testing program in diagnostic molecular pathology. Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2000;18:1349.
17. Ogino S. Education and training in diagnostic molecular pathology at the University of Pennsylvania. Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2001;19:202-203.
18. Ogino S. Pathology board examination in the United States: An update. Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2001;19:329.
19. Ogino S. Educational activities of American Society of Clinical Pathologists (ASCP). Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2001;19:434.
20. Ogino S. Education and training in clinical pathology in the United States. Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2001;19:538.
21. Ogino S. From residency and fellowship to faculty: My experience in the United States (in Japanese). Medical Research Information Center (MRIC) Mail Magazine 2005 September.
22. Ogino S. Molecular pathologic epidemiology (molecular epidemiologic pathology): an emerging field and a new role in cancer prevention (in Japanese). Japanese Researchers’ Academic Network of Greater Boston (JARAN) Newsletter 2010 January.

Narrative Report
I am a pathologist with a major research effort and 20% clinical effort. I have played various major leadership roles in international and national societies. I have received prestigious awards, Ramzi Cotran Young Investigator Award in 2011 from United States and Canadian Academy of Pathology (USCAP); and Executive Officer's Award in 2004 and Meritorious Service Award in 2012 from Association for Molecular Pathology (AMP). I have been elected to become Member of American Society for Clinical Investigation (ASCI) in 2014. I have also been selected as "the Most Influential Scientific Minds 2014" by Thomson Reuters.
My Area of Excellence is “Investigation”. With unique combined expertise in both molecular pathology and epidemiology, I have been developing integrative interdisciplinary science of “Molecular Pathological Epidemiology (MPE)”, which is defined as "epidemiology of molecular pathology and heterogeneity of disease". I have been conducting MPE research with a particular focus on colorectal cancer. My own research program has continuously been funded by NIH. Recent highlights of my MPE research include two studies published in The New England Journal of Medicine (NEJM), which examined colonoscopy screening and molecular features of colorectal cancer (R Nishihara et al. 2013), and interactive effects of aspirin and PIK3CA mutation in colorectal cancer (X Liao et al. 2012). The MPE paradigm has internationally been accepted, and the use of the MPE term has become widespread. I established “The International MPE Meeting” in 2013, and have been the Chairperson of its Program Committee. “The Second International MPE Meeting” went very successfully, with 20 expert speakers and over 150 participants from 16 countries and 21 US States, on December 4 and 5 in 2014. In addition to the establishment of the new field of MPE, I have been very innovative in research and have created novel paradigms, concepts and research framework, such as the “GWAS-MPE Approach” (S Ogino et al. Gut 2011), the “Unique Tumor Principle” (S Ogino et al. Expert Rev Mol Diagn 2012), the “Colorectal Continuum" model (M Yamauchi et al. Gut 2012), the “Unique Disease Principle” (S Ogino et al. Mod Pathol 2013), the “Etiologic Field Effect” concept (P Lochhead et al. Mod Pathol 2015), and the lifecourse - MPE model (A Nishi et al. Am J Prev Med 2015). I have also been very active in creating new research collaboration initiatives, including “MPE Working Group”, and “STROBE-MPE Initiative” (S Ogino et al. Am J Epidemiol 2012). I have published 183 original articles. I am the first, last, 2nd last, or co-last author in 116 original papers including those in NEJM (N=3), JAMA (N=3), Journal of Clinical Oncology (N=4), Journal of The National Cancer Institute (N=7), Science Translational Medicine (N=1), Gastroenterology (N=4), and Gut (N=6) (all with Impact Factor >10). As the 3rd last author, I played a major role as a molecular pathologist in two Nature papers (R Straussman et al. 2012; E Barry et al. 2013) and one Nature Genetics paper (M Giannakis et al. 2014).
With my unique combination of expertise in both molecular pathology and epidemiology, I have been teaching integration of molecular and population science at Harvard Medical School and affiliated hospitals, and Harvard T.H. Chan School of Public Health. I have served as a mentor for trainees with a wide variety of backgrounds in my interdisciplinary research laboratory, including pathologists, gastroenterologists, surgeons, epidemiologists, nutrition scientists, biostatisticians, and computational biologists. In addition, I regularly give a lecture for pathology residents and fellows as a part of molecular diagnostics lecture series.
As another Significant Supporting Activity, I have been serving as a molecular pathologist, with special expertise in colorectal cancer molecular tests. As an expert in gene and mutation nomenclature, I have been playing a major role in clinical molecular tests internationally (eg., for College of American Pathologists, Association for Molecular Pathology, and National Comprehensive Cancer Network) as well as locally in routine molecular tests and multi-mutational tests such as OncoPanel.
In summary, my research contribution has been very unique in integrating molecular pathology and population sciences as MPE, and has demonstrated widespread impact on biomedical and public health sciences. In addition, I am an expert molecular pathologist with effort in clinical service and in teaching and education, in very unique manners.


1   2   3   4   5   6   7


The database is protected by copyright ©dentisty.org 2016
send message

    Main page